The FDA has issued an establishment inspection report (EIR) for Biocon’s Bengaluru facility, where the drug maker manufactures biosimilars, and the FDA’s inspection of the facility, which took place during August 2019, is now closed.
The FDA has issued an establishment inspection report (EIR) for Biocon’s Bengaluru facility, where the drug maker manufactures biosimilars, and the FDA’s inspection of the facility, which took place during August 2019, is now closed.
The Bengaluru site also received an EU certification of good manufacturing practice in June of this year, and the FDA in October approved the company’s drug product filling line for 150-mg vials of trastuzumab after a September inspection.
In a statement announcing the EIR, Christiane Hamacher, PhD, the chief executive officer of Biocon Biologics, said, “The EIR for this facility reaffirms our manufacturing capabilities for high quality biosimilars to serve the needs of patients in the [United States].”
Hamacher added that the company’s biosimilar pegfilgrastim, Fulphila, for which it partners with Mylan, is already available in the United States, and that Biocon plans to make its biosimilar trastuzumab, Ogivri, commercially available “soon, leading to tremendous cost savings to the US healthcare system.” Once launched, Ogivri will join Amgen’s recently launched trastuzumab biosimilar, Kanjinti, in competing with the reference product, Herceptin, for the HER2-positive cancer market.
Biocon indicated that it hopes to serve 2.5 million patients in 2020, and 5 million patients—for revenues of $1 billion—by 2022. The company’s trastuzumab biosimilar will play a role in achieving those goals, as will an eventual insulin glargine biosimilar, although the company has not yet been successful in gaining FDA approval of its insulin glargine follow-on product despite 2 filings with the FDA.
Further growth will come, says Biocon, from launches of insulin aspart and bevacizumab biosimilars in global markets.
Biocon’s partner, Mylan, reported this week that its net sales in the North America segment of its business totaled $1.01 billion last quarter, or 14% lower than the same quarter last year. The decrease was largely due to lower volumes of sales for its existing products, like the EpiPen, and Mylan credited sales of Fulphila as having partially offset those lower sales numbers.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.